Share this article
Share this article
- OptraSCAN s Intelligent Tool CytoSiA – To Advance Cytology Screening Through Unmatched Image Quality And Artificial Intelligence Based Image Analysis Solution
SAN JOSE, Calif. and PUNE, India, May 25, 2021 /PRNewswire/ OptraSCAN®, the leading On-Demand Digital Pathology solution provider, today announced its intelligent solution CytoSiA for rapid yet affordable scanning and analyzing of liquid-based cytology slides and pap-smears. It is a complete solution consisting of OptraSCAN s digital pathology scanner, storage, and powerful artificial intelligence (AI) algorithms to assist pathologists and cytotechnologists in screening and detection of cervical cancer, pre-cancerous lesions, atypical cells, and all other cytologic categories. Multiple hospitals and pathology laboratories globally have already installed
Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
- Annamycin was designed to potentially become the first ever non-cardiotoxic anthracycline and has been shown in animal models to accumulate in the lungs at more than 30 times the level of doxorubicin (current standard of care)
- Patient enrollment on track to begin this quarter
- Interim data expected in the second half of 2022
- Annamycin granted Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases
News provided by
Share this article
HOUSTON, May 25, 2021 /PRNewswire/
Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis
Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) of the face or scalp and it acts through a selective antiproliferative mechanism of action
The positive opinion is based on the results from two pivotal phase III clinical trials which demonstrated complete clearance of AK lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than with vehicle, together with a good safety and tolerability profile
With the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), tirbanibulin edges closer to European Commission approval, expected in approximately 60 days
Diamyd® Phase IIb trial results published in Diabetes Care
News provided by
Share this article
STOCKHOLM, May 21, 2021 /PRNewswire/
Diabetes Care has published the results of DIAGNODE-2, a Phase IIb trial that evaluated intralymphatic administration of Diamyd Medical s lead drug candidate Diamyd
® (GAD-alum) in individuals recently diagnosed with type 1 diabetes. Results showed, in line with a published large-scale metaanalysis of clinical data, that while no treatment benefit was seen in the full patient population, three intralymphatic injections of Diamyd
® had a significant and positive effect on the preservation of insulin producing capacity in the predefined subgroup of individuals that carry the HLA DR3-DQ2 haplotype. In this subgroup of patients, more than 50% greater preservation of insulin producing capacity was observed at 15 months from baseline in those that received active treatment compared to placebo.
The Concinnity Company, Developer of Smarter Software for Clinical Trial Oversight, Partners with Cancer Research And Biostatistics (CRAB) to Provide the Ultimate Data Monitoring Committee Experience
News provided by
Share this article
Share this article
NASHVILLE, Tenn., May 20, 2021 /PRNewswire/ With the onset of the pandemic and a new lens on the critical importance of clinical trial data oversight, CRAB decided to expand its services for Data Monitoring Committees (DMCs or DSMBs). To ensure the success of this new line of service, CRAB worked to identify the best software solution for managing these important clinical trial oversight committees. They soon founded The Concinnity Company and its Cloud Concinnity